Clinical Trial Update: Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults [Phase 2]

View source ↗

Summary

This update reports that Exsulin's Phase 2 study of INGAP peptide for Type 1 diabetes mellitus has been terminated. The snippet does not provide efficacy or saf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• INGAP-Peptide (INGAP peptide)

Snippet

Sponsor: Exsulin Corporation | Conditions: Type 1 Diabetes Mellitus | Phase 2 | Status: TERMINATED